Using nanotechnology approaches, InnoSense can produce ultra-sensitive biosensors offering diverse diagnostic possibilities. Assembled in an array, these sensor chips detect the presence of targeted biomarkers resulting in cost-effective, fast, highly sensitive and selective diagnostic tools.

Innosense Corporation is developing Cell-Rx, a highly tunable biopolymer-based oral drug delivery system. Oral dosing has the highest rate of patient compliance. By developing an oral method for receiving sustained drug dosing, Cell-Rx can improve quality of life through extended release while reducing patient burden. The tunability of Cell-Rx is highlighted by achievement of sustained release for large hydrophilic proteins and small-molecule drugs. Innosense is developing two Cell-Rx formulations.